Phreesia, Inc. (NYSE:PHR) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 17.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,267,084 shares of the company's stock after selling 267,944 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 2.18% of Phreesia worth $31,880,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C increased its stake in shares of Phreesia by 133.6% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,271,832 shares of the company's stock worth $31,999,000 after acquiring an additional 727,384 shares during the period. Greenhouse Funds LLLP grew its stake in shares of Phreesia by 27.9% during the 4th quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company's stock valued at $72,307,000 after buying an additional 626,579 shares during the period. Park West Asset Management LLC purchased a new stake in Phreesia during the 4th quarter worth $10,657,000. Millennium Management LLC boosted its holdings in Phreesia by 83.2% in the 4th quarter. Millennium Management LLC now owns 653,634 shares of the company's stock worth $16,445,000 after acquiring an additional 296,863 shares during the period. Finally, ExodusPoint Capital Management LP boosted its stake in shares of Phreesia by 448.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after buying an additional 143,077 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company's stock.

Insider Activity at Phreesia

In other news, SVP David Linetsky sold 3,944 shares of the company's stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total transaction of $94,064.40. Following the completion of the transaction, the senior vice president now directly owns 221,738 shares of the company's stock, valued at approximately $5,288,451.30. This represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Allison C. Hoffman sold 1,213 shares of the stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total value of $28,881.53. Following the sale, the general counsel now directly owns 137,921 shares of the company's stock, valued at approximately $3,283,899.01. This represents a 0.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,474 shares of company stock valued at $1,023,208 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Phreesia Stock Performance

Phreesia stock traded up $0.12 during midday trading on Friday, reaching $24.55. 672,417 shares of the company traded hands, compared to its average volume of 440,425. The business has a 50 day moving average of $24.80 and a two-hundred day moving average of $25.28. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -16.70 and a beta of 0.74.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia's revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.05) EPS. As a group, research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analyst Weigh In

PHR has been the topic of a number of recent analyst reports. Citigroup restated a "buy" rating on shares of Phreesia in a research note on Wednesday. Wall Street Zen lowered shares of Phreesia from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. Needham & Company LLC restated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. KeyCorp decreased their price target on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Finally, Truist Financial upped their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.